Learn more

FIGENE LLC

Overview
  • Total Patents
    64
  • GoodIP Patent Rank
    22,872
About

FIGENE LLC has a total of 64 patent applications. Its first patent ever was published in 2014. It filed its patents most often in WIPO (World Intellectual Property Organization), United States and Canada. Its main competitors in its focus markets pharmaceuticals, biotechnology and medical technology are IDM IMMUNO DESIGNED MOLECULES, BOYALIFE INC and LISZIEWICZ JULIANNA.

Patent filings per year

Chart showing FIGENE LLCs patent filings per year from 1900 to 2020

Top inventors

# Name Total Patents
#1 O'Heeron Pete 60
#2 Ichim Thomas 55
#3 Comella Kristin 6
#4 Pete O'Heeron 1
#5 Oheeron Pete 1

Latest patents

Publication Filing date Title
WO2021076675A1 Prevention of recurrent miscarriages through administration of fibroblasts and fibroblast-educated paternal cells
WO2021076674A1 Fibroblast-based immunotherapy of graves disease
WO2021076465A1 Cannabidiol adjuvant therapy for treatment of disc degenerative disease
WO2021076525A1 Treatment of autoimmunity and transplant rejection through establishment and/or promotion of tolerogenic processes by fibroblast-mediated reprogramming of antigen presenting cells
US2021079350A1 Treatment of disc degenerative disease and stimulation of proteoglycan synthesis by fibroblast conditioned media and formulations thereo
WO2021050549A1 Fibroblast and fibroblast-immunocyte combinations for treatment of subconcussive- and concussive-associated neurological damage
WO2021050583A1 Treatment of traumatic encephalopathy by fibroblasts and therapeutic adjuvants
US2020405770A1 Administration of fibroblasts and derivatives thereof for treatment of type 2 diabetes
WO2020257774A1 Treatment of autism spectrum disorder and associated neuroinflammation using fibroblasts and derivatives thereof
WO2020252287A1 Enhancement of fibroblast therapeutic activity by rna
US2020376041A1 Concurrent activation of regenerative and tolerogenic processes by fibroblast-based compositions for the treatment of multiple sclerosis
WO2020243543A1 Fibroblast therapy for treatment of duchenne muscular dystrophy
WO2020227677A1 Fibroblast generated patient-specific vaccines
WO2020223145A1 Selection of fibroblast donors for optimization of allogeneic fibroblast-mediated regeneration
WO2020223155A1 Fibroblast cell therapy for treatment of osteoporosis
WO2020223148A1 Enhancement of fibroblast therapeutic activity by t cell modulation
US2020297774A1 Treatment of chronic obstructive pulmonary disease and lung degeneration using activated fibroblasts and exosome derivatives thereof
US2020297773A1 Treatment of opioid addiction using fibroblasts and products thereof
WO2020150567A1 Fibroblasts and microvesicles thereof for reduction of toxicity associated with cancer immunotherapy
WO2020146874A1 Fibroblast regenerative cells